Payment overview · 2025
General Payments
$13,991.85
64 reported records · 10 companies
Healthcare provider profile · identity verified
Branislav Schifferdecker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · OKLAHOMA CITY, OK · NPI 1013973304
Verified facts
What the public records show
CMS Open Payments records show Branislav Schifferdecker, M.D. received $13,991.85 in general payments during 2025 across 64 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 83.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 555 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 555 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 618 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1526 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11,644.33 | 83.2% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,375.00 | 9.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $288.22 | 2.1% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $274.81 | 2.0% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $149.74 | 1.1% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $115.76 | 0.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $71.49 | 0.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.52 | 0.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.98 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.00 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,375.00 | 5 |
| Food and Beverage | $1,616.85 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $13,019.33 | 22 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $274.81 | 17 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $248.88 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $115.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $101.86 | 11 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $71.49 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $47.88 | 4 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $39.34 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1526 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 555 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
424 | 89 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
555 | 142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
555 | 142 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
618 | 151 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1526 | 349 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2134 | 669 |
| Metoprolol Succinate | Metoprolol Succinate | 2094 | 648 |
| Clopidogrel | Clopidogrel Bisulfate | 1567 | 461 |
| Eliquis | Apixaban | 1526 | 349 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1376 | 407 |
| Amlodipine Besylate | Amlodipine Besylate | 1317 | 404 |
| Spironolactone | Spironolactone | 1222 | 415 |
| Losartan Potassium | Losartan Potassium | 1179 | 374 |
| Furosemide | Furosemide | 1089 | 374 |
| Ezetimibe | Ezetimibe | 782 | 247 |
| Potassium Chloride | Potassium Chloride | 689 | 228 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 646 | 189 |
| Entresto | Sacubitril/Valsartan | 618 | 151 |
| Jardiance | Empagliflozin | 555 | 142 |
| Amiodarone Hcl | Amiodarone Hcl | 550 | 193 |
| Lisinopril | Lisinopril | 529 | 155 |
| Carvedilol | Carvedilol | 525 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 144 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 460 | 161 |
| Farxiga | Dapagliflozin Propanediol | 424 | 89 |
| Torsemide | Torsemide | 371 | 128 |
| Hydralazine Hcl | Hydralazine Hcl | 307 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 307 | 90 |
| Xarelto | Rivaroxaban | 291 | 65 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 272 | 87 |
| Warfarin Sodium | Warfarin Sodium | 254 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 227 | 72 |
| Nitroglycerin | Nitroglycerin | 188 | 118 |
| Telmisartan | Telmisartan | 159 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 43 |
| Metformin Hcl | Metformin Hcl | 138 | 54 |
| Simvastatin | Simvastatin | 105 | 33 |
| Repatha Sureclick | Evolocumab | 97 | 18 |
| Brilinta | Ticagrelor | 80 | 18 |
| Omeprazole | Omeprazole | 79 | 20 |
| Gabapentin | Gabapentin | 78 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 18 |
| Digoxin | Digoxin | 64 | 18 |
| Atenolol | Atenolol | 62 | 15 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 60 | 20 |
| Valsartan | Valsartan | 60 | 18 |
| Multaq | Dronedarone Hcl | 59 | 12 |
| Allopurinol | Allopurinol | 53 | 16 |
| Sotalol | Sotalol Hcl | 50 | 18 |
| Eplerenone | Eplerenone | 48 | 12 |
| Labetalol Hcl | Labetalol Hcl | 46 | 15 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 18 |
| Midodrine Hcl | Midodrine Hcl | 44 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Praluent Pen | Alirocumab | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 13 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Famotidine | Famotidine | 36 | 12 |
| Cartia Xt | Diltiazem Hcl | 32 | 19 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Metolazone | Metolazone | 32 | 12 |
| Azithromycin | Azithromycin | 31 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 14 |
| Colchicine | Colchicine | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Lasix | Furosemide | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,991.85 · 64 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ELIQUIS, Extended Holter, JARDIANCE, LEQVIO, LifeVest, Ozempic, Rhythmia Mapping System, VERQUVO, VYNDAQEL, WAINUA, WATCHMAN FLX | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error